» Articles » PMID: 30696751

Delayed Febrile Response with Bloodstream Infections in Patients with Continuous-flow Left Ventricular Assist Devices

Abstract

Bloodstream infections (BSIs) are common in patients with continuous-flow left ventricular assist devices (CF-LVADs). Whether CF-LVADs modulate the febrile response to BSIs is unknown. We retrospectively compared the febrile response to BSIs in patients with heart failure (HF) with CF-LVADs versus a control population of patients with HF receiving inotropic infusions. BSIs were adjudicated using the Centers for Disease Control and Prevention and the National Healthcare Safety Network criteria. Febrile status (temperature ≥38°C, 100.4 °F), temperature at presentation with BSI, and the highest temperature within 72 hours (Tmax) were collected. We observed 59 BSIs in LVAD patients and 45 BSIs in controls. LVAD patients were more likely to be afebrile and to have a lower temperature at presentation than control (88% vs 58%, p=0.002, and 37°C ±0.7 vs 37.7°C ±1.0, p=0.0009, respectively). By 72 hours, the difference in afebrile status diminished (53% vs 44%, p=0.42), and the Tmax was similar between the LVAD and control groups (37.9°C±0.9 vs 38.2°C±0.8, respectively, p=0.10). In conclusion, at presentation with a BSI, the vast majority of CF-LVAD patients were afebrile, an event which occurred at a higher frequency when compared with patients with advanced HF on chronic inotropes via an indwelling venous catheter. These data alert clinicians to have a very low threshold to obtain blood cultures in CF-LVAD patients even in the absence of fever. Further study is needed to determine whether a delayed or diminished febrile response represents another pathophysiological consequence of CF-LVADs.

Citing Articles

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

OReilly M, Neill L, Collin S, Stone N, Springell D, Mensah J Hemasphere. 2024; 8(1):e29.

PMID: 38434533 PMC: 10878197. DOI: 10.1002/hem3.29.


An unusual case of fungaemia in an immunocompetent patient with a left ventricular assist device and an implantable cardiac device.

Tan S, Chung S, Tan T, Teo L, Tan B, Tan Y Access Microbiol. 2020; 2(9):acmi000148.

PMID: 33195980 PMC: 7656191. DOI: 10.1099/acmi.0.000148.

References
1.
Smedira N, Hoercher K, Lima B, Mountis M, Starling R, Thuita L . Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival. JACC Heart Fail. 2014; 1(1):31-9. DOI: 10.1016/j.jchf.2012.11.001. View

2.
Grosman-Rimon L, McDonald M, Jacobs I, Tumiati L, Pollock Bar-Ziv S, Shogilev D . Markers of inflammation in recipients of continuous-flow left ventricular assist devices. ASAIO J. 2014; 60(6):657-63. DOI: 10.1097/MAT.0000000000000129. View

3.
Frontera J, Starling R, Cho S, Nowacki A, Uchino K, Hussain M . Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. J Heart Lung Transplant. 2017; 36(6):673-683. DOI: 10.1016/j.healun.2016.12.010. View

4.
John R, Aaronson K, Pae W, Acker M, Hathaway D, Najarian K . Drive-line infections and sepsis in patients receiving the HVAD system as a left ventricular assist device. J Heart Lung Transplant. 2014; 33(10):1066-73. DOI: 10.1016/j.healun.2014.05.010. View

5.
Trachtenberg B, Cordero-Reyes A, Aldeiri M, Alvarez P, Bhimaraj A, Ashrith G . Persistent blood stream infection in patients supported with a continuous-flow left ventricular assist device is associated with an increased risk of cerebrovascular accidents. J Card Fail. 2014; 21(2):119-25. DOI: 10.1016/j.cardfail.2014.10.019. View